At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 120 enrolled
Drug / intervention
Fluarix/Influsplit SSW® (2013-2014 season)biological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study for Evaluation of Immunogenicity and Reactogenicity of Fluarix/Influsplit SSW 2013/2014 in People 18 Years of Age and Above
In Brief
A Phase 3 clinical trial evaluating Fluarix/Influsplit SSW® (2013-2014 season) for Influenza. Completed, enrolled 120 participants across 4 sites.
Detailed Summary
The purpose of this study is to assess, in adults 18 years of age and above, the immunogenicity and reactogenicity of the seasonal influenza vaccine, Fluarix/Influsplit SSW 2013/2014, containing the three vaccine influenza strains (two A strains and one B strain) for the 2013/2014 season.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
CountriesGermany
Collaborators--
Timeline
Phase 3CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJun 2013
Enrollment StartJul 2013
Primary CompletionAug 2013
TodayJul 2026
First PostedJun 24, 2013
Enrollment StartJul 1, 2013
Primary CompletionAug 2, 2013
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 13.0 years ago
Interventions
Fluarix/Influsplit SSW® (2013-2014 season)biological
1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm